Table 3 Estimated posterior median difference (and 95% credible intervals) in change from baseline for urinary incontinence, voiding and urgency episodes obtained from multivariate network meta-analysis incorporating class effects. Continued
From: Multivariate network meta-analysis incorporating class effects
Treatment | Code | Incontinence episodes†| Voiding episodes†| Urgency episodes†|
|---|---|---|---|---|
Sacral nerve stimulation | (81) | -8 (-9.54,-6.27) | -8.19 (-9.69,-6.49) | -8.49 (-10.11,-6.78) |
OnaBoNT-A 200u trigone sparing | (73) | -2.04 (-3.09,-1.29) | -2.26 (-3.31,-1.51) | -2.55 (-3.6,-1.74) |
Oxybutynin IR 2.5mg b.i.d + Salivary pastilles | (98) | -2.07 (-3.42,0.03) | -2.3 (-3.62,-0.22) | -2.64 (-3.85,-0.64) |
Electrostimulation + PFMT + BT | (97) | -1.78 (-2.58,-1.06) | -1.97 (-2.8,-1.25) | -2.3 (-3.21,-1.58) |
Solifenacin/trospium + placebo injection | (100) | -1.8 (-2.45,-0.79) | -2.01 (-2.67,-0.94) | -2.33 (-3.08,-1.22) |
OnaBoNT-A 100u bladder base + trigone | (79) | -1.78 (-3.31,-0.92) | -2.01 (-3.54,-1.14) | -2.35 (-4,-1.36) |
OnaBoNT-A 100u bladder body + trigone | (78) | -1.68 (-2.6,-0.92) | -1.89 (-2.85,-1.11) | -2.23 (-3.24,-1.4) |
OnaBoNTA 100u trigone sparing | (72) | -1.66 (-2.05,-1.3) | -1.73 (-2.07,-1.41) | -2.14 (-2.66,-1.7) |
Tolterodine ER 4mg q.d + Neurostimulation | (96) | -1.32 (-1.7,-0.95) | -1.57 (-2.05,-1.14) | -1.88 (-2.44,-1.43) |
Estriol 1mg intravesically | (131) | -1.52 (-2.88,-0.31) | -1.76 (-3.07,-0.58) | -2.06 (-3.4,-0.91) |
Trospium IR 15mg t.i.d + Physiotherapy | (91) | -1.16 (-1.95,-0.43) | -1.4 (-2.22,-0.62) | -1.74 (-2.58,-0.93) |
Estradiol 3mg intravaginally | (128) | -0.87 (-2.13,1.08) | -1.08 (-2.31,0.82) | -1.41 (-2.64,0.53) |
Solifenacin ER 10mg q.d | (30) | -0.82 (-1.06,-0.61) | -1.09 (-1.3,-0.9) | -1.37 (-1.74,-1.03) |
Tolterodine ER 2mg b.i.d + Oestrogen 0.625mg 2xwk | (99) | -0.68 (-1.23,-0.22) | -0.89 (-1.48,-0.39) | -1.22 (-1.88,-0.66) |
Tolterodine ER 4mg q.d + BT | (87) | -0.68 (-1.31,-0.07) | -0.88 (-1.61,-0.25) | -1.23 (-1.96,-0.57) |
Pregabalin 150mg b.i.d + Tolterodine ER 4mg q.d | (102) | -0.85 (-1.42,-0.2) | -1.09 (-1.65,-0.46) | -1.41 (-2.05,-0.69) |
Fesoterodine ER 8mg q.d | (26) | -0.69 (-0.87,-0.49) | -0.92 (-1.1,-0.72) | -1.25 (-1.6,-0.9) |
Imidafenacin IR 0.25mg b.i.d | (37) | -0.72 (-1.32,-0.17) | -0.96 (-1.55,-0.34) | -1.28 (-1.98,-0.62) |
Solifenacin ER (5mg-10mg) q.d | (31) | -0.68 (-0.9,-0.42) | -0.84 (-1.06,-0.61) | -1.2 (-1.54,-0.87) |
Solifenacin ER 5mg - 15mg q.d | (34) | -0.64 (-1,-0.27) | -0.87 (-1.29,-0.45) | -1.2 (-1.66,-0.75) |
Mirabegron 100mg b.i.d | (48) | -0.68 (-1.06,-0.4) | -0.87 (-1.27,-0.6) | -1.2 (-1.68,-0.88) |
Solabegron 125mg b.i.d | (55) | -0.62 (-0.9,-0.34) | -0.84 (-1.12,-0.59) | -1.16 (-1.58,-0.79) |
Propiverine ER 30mg b.i.d | (42) | -0.61 (-1.81,-0.1) | -0.85 (-2.06,-0.37) | -1.18 (-2.42,-0.6) |
Darifenacin ER 30mg q.d | (38) | -0.59 (-1.15,-0.05) | -0.8 (-1.41,-0.2) | -1.15 (-1.73,-0.54) |
Mirabegron ER 25mg q.d | (50) | -0.63 (-0.87,-0.42) | -0.85 (-1.05,-0.64) | -1.16 (-1.48,-0.84) |
Mirabegron IR 150mg b.i.d | (49) | -0.61 (-0.91,-0.29) | -0.87 (-1.14,-0.55) | -1.18 (-1.53,-0.81) |
Mirabegron ER 100mg q.d | (52) | -0.62 (-0.81,-0.44) | -0.8 (-0.96,-0.61) | -1.15 (-1.47,-0.87) |
Mirabegron ER 200mg q.d | (53) | -0.62 (-0.91,-0.27) | -0.83 (-1.13,-0.47) | -1.17 (-1.53,-0.79) |
Oxybutynin ER 10mg q.d | (8) | -0.58 (-1.09,-0.25) | -0.81 (-1.27,-0.47) | -1.14 (-1.57,-0.7) |
Propiverine ER 30mg q.d | (42) | -0.56 (-1.05,-0.17) | -0.76 (-1.33,-0.37) | -1.08 (-1.72,-0.66) |
Oxybutynin IR 3mg t.i.d | (19) | -0.6 (-0.94,-0.3) | -0.75 (-1.12,-0.45) | -1.09 (-1.56,-0.7) |
Mirabegron ER 50mg q.d | (51) | -0.59 (-0.78,-0.42) | -0.84 (-0.99,-0.67) | -1.15 (-1.45,-0.84) |
Solifenacin ER 5mg q.d | (29) | -0.6 (-0.8,-0.38) | -0.74 (-0.92,-0.58) | -1.14 (-1.48,-0.83) |
Tolterodine IR 2mg b.i.d + BT | (93) | -0.57 (-1,0) | -0.86 (-1.28,-0.2) | -1.15 (-1.7,-0.47) |
Cizolirtine Citrate 400mg b.i.d | (57) | -0.56 (-1.1,-0.05) | -0.8 (-1.37,-0.25) | -1.16 (-1.78,-0.56) |
Trospium ER 60mg q.d | (44) | -0.55 (-0.92,-0.21) | -0.75 (-1.13,-0.41) | -1.08 (-1.59,-0.61) |
Propiverine IR 45mg t.i.d | (118) | -0.52 (-1.14,0.1) | -0.73 (-1.35,-0.15) | -1.06 (-1.73,-0.39) |
Tolterodine IR 2mg b.i.d + Pilocarpine 9mg b.i.d | (101) | -0.5 (-0.81,-0.23) | -0.74 (-1.11,-0.43) | -1.07 (-1.53,-0.68) |
Fesoterodine ER 4mg q.d | (25) | -0.49 (-0.66,-0.32) | -0.7 (-0.86,-0.53) | -1.03 (-1.38,-0.72) |
Pregabalin 150mg b.i.d | (62) | -0.5 (-1.08,0.12) | -0.75 (-1.3,-0.18) | -1.06 (-1.74,-0.35) |
Darifenacin ER 15mg q.d | (40) | -0.46 (-0.83,0) | -0.65 (-1.05,-0.17) | -0.99 (-1.48,-0.47) |
Propiverine IR 15mg b.i.d | (43) | -0.46 (-0.88,-0.1) | -0.62 (-1.07,-0.27) | -0.98 (-1.56,-0.58) |
Tolterodine ER 4mg q.d | (4) | -0.5 (-0.6,-0.4) | -0.62 (-0.74,-0.52) | -0.99 (-1.29,-0.75) |
Oxybutynin IR 5mg t.i.d | (7) | -0.45 (-0.78,-0.18) | -0.64 (-0.93,-0.36) | -0.98 (-1.37,-0.61) |
Propiverine ER 20mg q.d | (41) | -0.42 (-0.6,-0.22) | -0.65 (-0.84,-0.48) | -0.98 (-1.35,-0.67) |
Tolterodine IR 2mg b.i.d | (5) | -0.44 (-0.57,-0.3) | -0.67 (-0.82,-0.53) | -0.98 (-1.31,-0.7) |
Propiverine ER 60mg q.d | (119) | -0.41 (-0.89,0.72) | -0.6 (-1.09,0.44) | -0.92 (-1.55,0.23) |
Oxybutynin intravesically 5mg t.i.d | (14) | -0.41 (-0.97,-0.02) | -0.61 (-1.17,-0.23) | -0.96 (-1.52,-0.52) |
Oxybutynin IR 2.5-5mg b.i.d | (24) | -0.46 (-0.8,-0.16) | -0.63 (-0.95,-0.38) | -1 (-1.36,-0.6) |
Oxybutynin chloride topical gel 1g q.d | (13) | -0.43 (-0.78,-0.13) | -0.64 (-0.97,-0.35) | -0.99 (-1.35,-0.59) |
Oxybutynin vaginal ring 6mg q.d | (17) | -0.39 (-0.78,0.01) | -0.63 (-1.01,-0.23) | -0.95 (-1.4,-0.44) |
Tolterodine IR 2mg b.i.d + PFMT | (95) | -0.44 (-0.98,0.42) | -0.65 (-1.23,0.2) | -0.98 (-1.62,-0.2) |
PFMT + BT | (89) | -0.38 (-0.83,0.03) | -0.66 (-1.16,-0.18) | -0.95 (-1.55,-0.44) |
Tolterodine IR 1mg b.i.d | (6) | -0.39 (-0.64,-0.08) | -0.62 (-0.91,-0.31) | -0.94 (-1.35,-0.58) |
Fesoterodine ER 4mg-8mg q.d | (27) | -0.37 (-0.59,-0.17) | -0.67 (-0.86,-0.46) | -0.96 (-1.33,-0.62) |
Oxybutynin gel 84mg/day | (134) | -0.37 (-0.76,0) | -0.63 (-0.99,-0.28) | -0.96 (-1.33,-0.51) |
Oxybutynin transdermal 3.9mg/day | (10) | -0.38 (-0.63,-0.14) | -0.61 (-0.86,-0.35) | -0.94 (-1.29,-0.58) |
Oxybutynin vaginal ring 4mg q.d | (16) | -0.37 (-0.67,-0.03) | -0.56 (-0.87,-0.22) | -0.92 (-1.31,-0.48) |
Imidafenacin 0.1mg b.i.d | (36) | -0.38 (-0.69,-0.1) | -0.55 (-0.81,-0.29) | -0.9 (-1.3,-0.5) |
Terodiline 25mg b.i.d | (28) | -0.37 (-0.78,0.14) | -0.51 (-0.9,-0.05) | -0.88 (-1.44,-0.3) |
Darifenacin ER 7.5mg q.d | (39) | -0.35 (-0.81,0.19) | -0.58 (-1.08,0.02) | -0.92 (-1.46,-0.29) |
Oxybutynin gel 56mg/day | (135) | -0.35 (-0.69,0.06) | -0.52 (-0.82,-0.1) | -0.88 (-1.3,-0.38) |
Oxbutynin patch 73.5mg | (15) | -0.34 (-0.57,-0.02) | -0.56 (-0.86,-0.15) | -0.89 (-1.27,-0.45) |
Elocalcitol 75mg | (70) | -0.37 (-0.89,0.06) | -0.5 (-1.06,-0.07) | -0.89 (-1.57,-0.38) |
Oxybutynin 20mg intravesically q.d | (106) | -0.33 (-0.75,0.42) | -0.55 (-0.95,0.27) | -0.9 (-1.34,-0.05) |
Imidafenacin 0.05mg b.i.d | (35) | -0.32 (-0.76,0.23) | -0.57 (-1.03,0.03) | -0.9 (-1.42,-0.22) |
Oxybutynin ER 15mg q.d | (9) | -0.31 (-0.78,0.12) | -0.53 (-0.98,-0.07) | -0.88 (-1.32,-0.31) |
Oxybutynin IR 5-20mg | (23) | -0.29 (-0.67,0.26) | -0.52 (-0.9,0.07) | -0.85 (-1.32,-0.13) |
Oxybutynin ER 5-30mg q.d | (22) | -0.3 (-0.63,0.02) | -0.5 (-0.88,-0.12) | -0.87 (-1.27,-0.39) |
Trospium chloride IR 45mg t.i.d | (47) | -0.33 (-0.81,0.18) | -0.55 (-0.95,-0.12) | -0.89 (-1.38,-0.35) |
Cizolirtine citrate 200mg b.i.d | (56) | -0.22 (-1.26,0.73) | -0.46 (-1.48,0.54) | -0.77 (-1.87,0.26) |
Pelvic floor muscle training (PFMT)/Physiotherapy | (84) | -0.33 (-0.82,0.15) | -0.59 (-1.17,-0.01) | -0.89 (-1.54,-0.35) |
Oxybutynin transdermal 1.3mg/day | (11) | -0.27 (-0.56,0.14) | -0.48 (-0.78,-0.04) | -0.82 (-1.26,-0.29) |
Elocalcitol 150mg | (69) | -0.34 (-0.78,0.19) | -0.55 (-1.05,-0.04) | -0.86 (-1.48,-0.27) |
Oxybutynin ER 2.5mg q.d | (20) | -0.27 (-0.68,0.36) | -0.54 (-0.95,0.15) | -0.86 (-1.33,-0.04) |
Duloxetine 40mg b.i.d | (65) | -0.3 (-0.86,0.26) | -0.52 (-1.16,0.09) | -0.86 (-1.56,-0.16) |
Bladder Training (BT)/ Behaviour Therapy | (85) | -0.26 (-0.56,0.05) | -0.45 (-0.8,-0.13) | -0.8 (-1.24,-0.4) |
Solabegron IR 50mg b.i.d | (54) | -0.24 (-0.52,0.05) | -0.46 (-0.74,-0.18) | -0.79 (-1.22,-0.4) |
Oxybutynin IR 2.5mg t.i.d | (21) | -0.19 (-0.45,0.1) | -0.58 (-0.99,-0.17) | -0.77 (-1.17,-0.34) |
Oxybutynin transdermal 2.6mg/day | (12) | -0.18 (-0.52,0.35) | -0.43 (-0.75,0.16) | -0.77 (-1.2,-0.11) |
Pregabalin 75mg b.i.d + Tolterodine ER 2mg q.d | (103) | -0.24 (-0.67,0.24) | -0.48 (-0.9,-0.04) | -0.78 (-1.33,-0.25) |
Oxybutynin ER 2.5mg q.d + BT | (92) | -0.35 (-1.14,0.48) | -0.57 (-1.35,0.27) | -0.88 (-1.75,0.03) |
Oxybutynin IR 5mg b.i.d | (18) | -0.15 (-0.49,0.35) | -0.39 (-0.78,0.15) | -0.75 (-1.19,-0.09) |
Lipo-BoNTA 200U | (138) | -0.04 (-0.92,0.78) | -0.26 (-1.21,0.61) | -0.57 (-1.53,0.29) |
Serlopitant 0.25mg q.d | (107) | -0.08 (-0.56,0.45) | -0.31 (-0.79,0.23) | -0.64 (-1.2,-0.01) |
Serlopitant 4mg q.d | (109) | -0.07 (-0.61,0.44) | -0.3 (-0.81,0.24) | -0.63 (-1.21,0.01) |
Tarafenacin 0.4mg q.d | (82) | -0.19 (-0.82,0.53) | -0.43 (-1.04,0.29) | -0.75 (-1.4,-0.02) |
Electrostimulation + vaginal oestrogen cream 1.25mg/day | (133) | -0.08 (-0.77,0.61) | -0.22 (-0.91,0.5) | -0.68 (-1.51,0.16) |
Electrostimulation | (80) | -0.05 (-0.48,0.37) | -0.35 (-0.89,0.15) | -0.76 (-1.44,-0.16) |
Serlopitant 1mg q.d | (108) | 0.06 (-0.48,0.61) | -0.15 (-0.63,0.39) | -0.5 (-1.08,0.15) |
Estradiol 25mg | (68) | 0.01 (-0.4,0.51) | -0.19 (-0.68,0.32) | -0.53 (-1.09,0.04) |
Placebo | (1) | NA | NA | NA |
Netupitant 200mg q.d | (112) | -0.09 (-0.98,0.74) | -0.3 (-1.23,0.51) | -0.63 (-1.54,0.2) |
Netupitant 100mg q.d | (111) | -0.04 (-0.84,1.06) | -0.25 (-1.08,0.84) | -0.59 (-1.48,0.47) |
Tarafenacin 0.2mg q.d | (90) | 0.01 (-0.66,0.7) | -0.18 (-0.89,0.51) | -0.52 (-1.25,0.14) |
Trospium IR 15mg t.i.d | (46) | -0.03 (-0.74,0.71) | -0.18 (-1.02,0.58) | -0.54 (-1.39,0.27) |
ZD0947IL 25mg/day | (58) | 0.07 (-0.61,0.87) | -0.1 (-0.84,0.67) | -0.42 (-1.28,0.24) |
Netupitant 50mg q.d | (110) | 0.06 (-0.61,0.81) | -0.14 (-0.83,0.51) | -0.48 (-1.33,0.22) |
Electromagnetic stimulation | (125) | -1.25 (-4.03,0.42) | -1.47 (-4.25,0.17) | -1.85 (-4.57,-0.06) |
Oxybutynin ER 5-30mg/day + Behaviour therapy | (22) | 0.19 (-0.63,1.05) | -0.04 (-0.92,0.84) | -0.4 (-1.24,0.6) |
ONO-8539 100mg b.i.d | (60) | 0.15 (-0.43,0.77) | -0.04 (-0.62,0.55) | -0.37 (-1,0.3) |
Percutaneous tibial nerve stimulation | (83) | -0.42 (-1.06,0.4) | -0.65 (-1.33,0.13) | -0.95 (-1.74,-0.22) |
Vaginal oestrogen cream 1.25mg/day | (132) | 0.28 (-0.22,0.75) | 0 (-0.57,0.52) | -0.26 (-0.91,0.34) |
Flavoxate chloride 200mg q.d | (64) | 0.28 (-0.35,1.19) | 0.05 (-0.59,0.97) | -0.29 (-0.93,0.64) |
Resiniferatoxin 50nM | (67) | 0.08 (-1.43,1.12) | -0.15 (-1.68,0.88) | -0.47 (-2.07,0.63) |
Emepronium bromide ER 200mg q.d | (63) | 0.36 (-0.65,1.17) | 0.15 (-0.86,0.98) | -0.21 (-1.17,0.65) |
ONO-8539 300mg b.i.d | (61) | 0.43 (-0.11,1.07) | 0.2 (-0.31,0.85) | -0.17 (-0.67,0.61) |
Propantheline Bromide 15mg t.i.d | (113) | 0.69 (-0.88,1.59) | 0.46 (-0.99,1.35) | 0.11 (-1.41,1.12) |
Estradiol 1mg intravaginally | (127) | 1.02 (-0.45,2.47) | 0.82 (-0.61,2.26) | 0.46 (-0.95,1.94) |
ONO-8539 30mg b.i.d | (59) | 0.58 (-0.1,1.2) | 0.35 (-0.32,0.98) | 0.02 (-0.67,0.7) |
Control | (2) | 0.49 (0,1.09) | 0.33 (-0.1,0.94) | -0.02 (-0.62,0.6) |
Reflexology | (71) | 0.46 (-0.12,1.22) | 0.22 (-0.45,0.97) | -0.06 (-0.79,0.7) |
Sham Therapy | (3) | 0.2 (-0.45,0.96) | 0 (-0.65,0.73) | -0.34 (-1.08,0.34) |
Naftopidil 25mg q.d | (114) | 4.06 (2.41,5.02) | 3.8 (2.21,4.79) | 3.48 (1.81,4.49) |
Solifenacin ER 5mg q.d + Naftopidil 25mg q.d | (115) | 5.19 (3.67,7.37) | 4.95 (3.47,7.15) | 4.6 (3.22,6.91) |